What is Aquestive Therapeutics, Inc.'s total revenue?

Aquestive Therapeutics, Inc. (AQST) reported total revenue of $14.45M in Q1 2026.

How has Aquestive Therapeutics, Inc.'s total revenue changed year-over-year?

Aquestive Therapeutics, Inc.'s total revenue increased by 65.7% year-over-year, from $8.72M to $14.45M.

What is the long-term trend for Aquestive Therapeutics, Inc.'s total revenue?

Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s total revenue has grown at a -3.2% compound annual growth rate (CAGR), from $50.83M to $44.55M.

What does total revenue mean?

The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Aquestive Therapeutics, Inc. AQST Total Revenue

Total Revenue at other companies

Indivior Pharmaceuticals, Inc. INDV

$317M+19.2%

ARS Pharmaceuticals, Inc.SPRY

$22.68M+184%

ViatrisVTRS

$3.52B+8.1%

AMP

Amphastar PharmaceuticalsAMPH

$171.17M+0.4%

AptarGroupATR

$982.87M+10.8%

AbbVieABBV

$15B+12.4%

Segments

By product

See full

Manufacture and supply revenue$8.79M—

License and royalty revenue a$500K-40.4%

Co-development and research fees$258K—

Proprietary product revenue, net$0—

By segment

See full

Reportable Segment$14.45M+65.7%

By geography

See full

United States$13.25M—

Other financials

Income statement

See full

Gross profit$11.0M+117%

Operating income-$4.2M+78.3%

Net income-$8.1M+64.9%

EPS (diluted)-$0.07+70.8%

Balance sheet

See full

Cash & equivalents$110.7M+61.3%

Total debt$64.4M+7.4%

Total equity-$34.1M+44.1%

Total assets$141.1M+38.0%

Cash flow

See full

Operating cash flow-$14.8M+36.7%

CapEx$52.0K-61.5%

Free cash flow-$14.9M+36.9%

Valuation

See full

Market cap$560.13M+73.5%

Enterprise value$513.76M+63.6%

P/S11.1×+5.2×

Profitability

See full

Gross margin63.5%-4.9pp

Operating margin-111.2%+96.3pp

Net margin-137.1%+80.7pp

FCF margin-88.2%-2.2pp

Returns & leverage

See full

Return on equity145.1%—

Debt / equity-1.9×—

Current ratio4.1×-0.8×

Where this comes from

Reported directly by Aquestive Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aquestive Therapeutics, Inc.'s total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aquestive Therapeutics, Inc.'s total revenue?: Aquestive Therapeutics, Inc. (AQST) reported total revenue of $14.45M in Q1 2026.
How has Aquestive Therapeutics, Inc.'s total revenue changed year-over-year?: Aquestive Therapeutics, Inc.'s total revenue increased by 65.7% year-over-year, from $8.72M to $14.45M.
What is the long-term trend for Aquestive Therapeutics, Inc.'s total revenue?: Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s total revenue has grown at a -3.2% compound annual growth rate (CAGR), from $50.83M to $44.55M.
What does total revenue mean?: The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.